Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
| Autor: | Chiara Cattaneo, Jon Salmanton-García, Francesco Marchesi, Shaimaa El-Ashwah, Federico Itri, Barbora Weinbergerová, Maria Gomes Da Silva, Michelina Dargenio, Julio Dávila-Valls, Sonia Martín-Pérez, Francesca Farina, Jaap Van Doesum, Toni Valković, Caroline Besson, Christian Bjørn Poulsen, Alberto López-García, Pavel Žák, Martin Schönlein, Klára Piukovics, Ozren Jaksic, Alba Cabirta, Natasha Ali, Uluhan Sili, Nicola Fracchiolla, Giulia Dragonetti, Tatjana Adžić-Vukičević, Monia Marchetti, Marina Machado, Andreas Glenthøj, Olimpia Finizio, Fatih Demirkan, Ola Blennow, Maria Chiara Tisi, Ali S. Omrani, Milan Navrátil, Zdeněk Ráčil, Jan Novák, Gabriele Magliano, Moraima Jiménez, Carolina Garcia-Vidal, Nurettin Erben, Maria Ilaria Del Principe, Caterina Buquicchio, Rui Bergantim, Josip Batinić, Murtadha Al-Khabori, Luisa Verga, Tomáš Szotkowski, Michail Samarkos, Irati Ormazabal-Vélez, Stef Meers, Johan Maertens, László Imre Pinczés, Martin Hoenigl, Ľuboš Drgoňa, Annarosa Cuccaro, Yavuz M. Bilgin, Avinash Aujayeb, Laman Rahimli, Stefanie Gräfe, Mariarita Sciumè, Miloš Mladenović, Gökçe Melis Çolak, Maria Vittoria Sacchi, Anna Nordlander, Caroline Berg Venemyr, Michaela Hanáková, Nicole García-Poutón, Ziad Emarah, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Raul Cordoba, Gustavo-Adolfo Méndez, Monika M. Biernat, Oliver A. Cornely, Livio Pagano |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Cattaneo C] Hematology Unit, ASST-Spedali Civili, Brescia, Italy. [Salmanton-García J] University of Cologne, Faculty of Medicine, University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [El-Ashwah S] Oncology Center, Mansoura University, Mansoura, Egypt. [Itri F] San Luigi Gonzaga Hospital, Orbassano, Italy. [Weinbergerová B] Masaryk University and University Hospital Brno—Department of Internal Medicine, Hematology and Oncology, Brno, Czech Republic. [Cabirta A] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Jiménez M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Cattaneo C., Salmanton-García J., Marchesi F., El-Ashwah S., Itri F., Weinbergerová B., Gomes Da Silva M., Dargenio M., Dávila-Valls J., Martín-Pérez S., et al., Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)., HAL UVSQ, Équipe |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Internal Diseases
Cancer Research Sağlık Bilimleri Other subheadings::Other subheadings::/drug therapy [Other subheadings] İç Hastalıkları Clinical Medicine (MED) RECOMMENDATIONS Sang - Càncer - Tractament BİYOKİMYA VE MOLEKÜLER BİYOLOJİ INFECTION virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] haematological malignancy onset Klinik Tıp (MED) 03.02. Klinikai orvostan Klinik Tıp treatment Temel Bilimler COVID-19 outcome prognostic factors Life Sciences Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] Onkoloji Tıp MOLECULAR BIOLOGY & GENETICS Oncology Medicine ONKOLOJİ Natural Sciences BIOCHEMISTRY & MOLECULAR BIOLOGY Life Sciences & Biomedicine Sitogenetik Life Sciences (LIFE) Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] [SDV.CAN]Life Sciences [q-bio]/Cancer Molecular Biology and Genetics PANEL [SDV.CAN] Life Sciences [q-bio]/Cancer Yaşam Bilimleri Health Sciences Cytogenetic neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES] Moleküler Biyoloji ve Genetik ACUTE LYMPHOBLASTIC-LEUKEMIA Internal Medicine Sciences Science & Technology diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Dahili Tıp Bilimleri CLINICAL MEDICINE Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES] Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Settore MED/15 Settore MED/15 - MALATTIE DEL SANGUE Sang - Càncer - Diagnòstic Yaşam Bilimleri (LIFE) Avaluació de resultats (Assistència sanitària) COVID-19 (Malaltia) - Diagnòstic Kanser Araştırmaları |
| Zdroj: | Cattaneo, C, Salmanton-García, J, Marchesi, F, El-Ashwah, S, Itri, F, Weinbergerová, B, Gomes Da Silva, M, Dargenio, M, Dávila-Valls, J, Martín-Pérez, S, Farina, F, Van Doesum, J, Valković, T, Besson, C, Poulsen, C B, López-García, A, Žák, P, Schönlein, M, Piukovics, K, Jaksic, O, Cabirta, A, Ali, N, Sili, U, Fracchiolla, N, Dragonetti, G, Adžić-Vukičević, T, Marchetti, M, Machado, M, Glenthøj, A, Finizio, O, Demirkan, F, Blennow, O, Tisi, M C, Omrani, A S, Navrátil, M, Ráčil, Z, Novák, J, Magliano, G, Jiménez, M, Garcia-Vidal, C, Erben, N, Del Principe, M I, Buquicchio, C, Bergantim, R, Batinić, J, Al-Khabori, M, Verga, L, Szotkowski, T, Samarkos, M, Ormazabal-Vélez, I, Meers, S, Maertens, J, Pinczés, L I, Hoenigl, M, Drgoňa, Ľ, Cuccaro, A, Bilgin, Y M, Aujayeb, A, Rahimli, L, Gräfe, S, Sciumè, M, Mladenović, M, Çolak, G M, Sacchi, M V, Nordlander, A, Berg Venemyr, C, Hanáková, M, García-Poutón, N, Emarah, Z, Zambrotta, G P M, Nunes Rodrigues, R, Cordoba, R, Méndez, G A, Biernat, M M, Cornely, O A & Pagano, L 2022, ' Simultaneous Onset of Haematological Malignancy and COVID : An Epicovideha Survey ', Cancers, vol. 14, no. 22, 5530 . https://doi.org/10.3390/cancers14225530 Cancers; Volume 14; Issue 22; Pages: 5530 Cancers, 14(22):5530. MDPI AG Scientia Cancers Cancers, 2022, 14 (22), pp.5530. ⟨10.3390/cancers14225530⟩ |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers14225530 |
| Popis: | Simple Summary Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, >= 2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, >= 2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|